Drugs / BBV154
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04751682 | Mar → Jun 2021 | Orthocoronavirinae infectious disease | Bharat Biotech International Limited | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05639998 | Sep 2021 → Mar 2022 | COVID-19 | Bharat Biotech International Limited | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05522335 Comparator | Apr → Jul 2022 | COVID-19 | Bharat Biotech International Limited | Unknown | No outcome recorded |
| Phase 3 | NCT05567471 Comparator | Feb → May 2022 | COVID-19 | Bharat Biotech International Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBV154 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05567471 ↗ |
| Modality | Vaccine | “Replication deficient Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine” NCT04751682 ↗ |
| Route | Intranasal | “via intranasal route” NCT04751682 ↗ |